Tandem Diabetes Care Reports Second Quarter 2014 Financial Results

SAN DIEGO, July 31, 2014 -- Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today reported its financial results for the quarter ended June 30, 2014.

In comparing the second quarter of 2014 to the same period of 2013:

  • Sales grew 86 percent to $10.3 million from $5.5 million
  • t:slim Pump shipments grew 64 percent to 2,235 pumps from 1,363 pumps

ZELTIQ Announces Second Quarter 2014 Financial Results

Increases Full Year 2014 Revenue Guidance to $160 - $165 Million Increases Full Year 2014 Adjusted EBITDA Guidance to Profitability

PLEASANTON, CA--(Jul 29, 2014) -  ZELTIQ (NASDAQ: ZLTQ)

  • Total revenue of $47.1 million, up 79% compared to $26.3 million in Q2 2013
  • Adjusted EBITDA margin of 12%
  • 208 systems shipped, compared to 136 systems in Q2 2013, bringing total system installed base to 2,562 systems
  • 166,116 revenue cycles, up 63% from Q2 2013

NASDAQ Welcomes Intersect ENT (NASDAQ: XENT) to The NASDAQ Stock Market

NEW YORK, July 24, 2014 -- The NASDAQ OMX Group, Inc. (NDAQ) announced that trading of Intersect ENT (XENT), a commercial drug-device company, commenced on The NASDAQ Stock Market on July 24, 2014.

Intersect ENT, Inc. is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT's drug-eluting bioabsorbable implant technology enables targeted and sustained release of therapeutic agents. Intersect ENT's initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved for use in patients with chronic sinusitis. Intersect ENT is developing new, less invasive and more cost-effective drug-eluting bioabsorbable treatment options for the management of chronic sinusitis in the physician office setting to provide benefits for patients, physicians and payors.

Aurora Spine Announces First Surgery Using Zip Graft(TM) Bone Dowel

CARLSBAD, CALIFORNIA--( July 25, 2014) - Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first U.S. surgery using the ZIP Graft ™ pre-packaged sterile bone dowel. The surgery was performed at Madison County Hospital in London, Ohio by Dr. Won Song.

The Aurora Zip Graft is a bone dowel designed specifically to fit into the ZIP™ MIS Interspinous Fusion System. "We are very excited to see the Zip Graft used in conjunction with the Zip MIS fusion device. The allograft bone dowels are designed and sized to fit into our devices thus creating an integrated fit every time" stated Doug Johnson VP of Sales, East.

Intuitive Surgical Announces Second Quarter Earnings

SUNNYVALE, Calif., July 22, 2014-- Intuitive Surgical, Inc. (ISRG), the industry leader in robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2014.

Q2 Highlights

In the second quarter of 2014, worldwide procedures grew 9% over the second quarter of 2013, up 8% sequentially over the first quarter of 2014. The Company shipped 96 systems during the second quarter, compared with 87 systems shipped in the first quarter of 2014. In addition,

  • The Company launched the da Vinci Xi system in the U.S. Fifty of the ninety-six systems shipped in the quarter were da Vinci Xi models.
  • The Company entered into an agreement with its Japanese distributor to transition the business to a direct market in June.
  • The Company's vessel sealer was cleared by the FDA for use with da Vinci Xi.
  • The Company received FDA clearance of da Vinci SP 999 and commenced efforts to develop the product towards commercialization.